All In Biotech

Drug Trial Radar · NCT02682927

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 262 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

262

Actual

Start

Jan 15, 2016

Primary completion

Jul 29, 2020

Study completion Jul 29, 2020

Sponsor

Sponsor type
Industry
First posted
Feb 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study 1 and Study 3 are the prospective, merged analyses of 2 identical double-blind, placebo-controlled studies, ZX008-1501 and ZX008-1502, to assess the efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric and young adult subjects with Dravet syndrome. Study 1501 and Study 1502 were conducted in parallel; Study 1501 was conducted at approximately 30 study sites in North America; Study 1502 was conducted at approximately 30 study sites in Europe, Asia and Australia. Upon completion of the Baseline Period after initial Screening and Baseline charting of seizure frequency, subjects who qualified for the studies were randomized (1:1:1) in a double-blind manner to receive either 1 of 2 doses of ZX008 (0.2 mg/kg/day or 0.8 mg/kg/day; maximum dose: 30 mg/day) or placebo. Randomization was stratified by age group (\< 6 years, ≥6 to 18 years) to achieve balance across treatment arms, with the target of 25% of subjects in each age group. All subjects were titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects continued treatment at their randomly assigned dose over a 12-week Maintenance Period. Subjects exiting the study underwent a 2-week taper, unless they enrolled in a follow-on study. Subjects were followed for post-study safety monitoring.

Conditions

  • Dravet Syndrome
  • Seizure Disorder

Interventions

  • ZX008 (Fenfluramine Hydrochloride)Drug

    ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.

  • Matching PlaceboDrug

    Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to PlaceboTime frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]

Locations

55 sites in 11 countries. Site status is shown where the registry gives one.

  • Phoenix Children's

    Phoenix, Arizona

  • Center for Neurosciences - Tucson

    Tucson, Arizona

  • Rady Children's Hospital San Diego

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • The Children's Hospital Colorado

    Aurora, Colorado

  • NW FL Clinical Research Group, LLC

    Gulf Breeze, Florida

  • Miami Children's Hospital Brain Institute

    Miami, Florida

  • Neurology and Epilepsy Research Center

    Orlando, Florida

  • Panda Neurology

    Atlanta, Georgia

  • Children's Hospital of Chicago

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Saint Barnabas Medical Center

    Livingston, New Jersey

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Cook Children's Medical Center

    Fort Worth, Texas

  • University of Utah

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • MultiCare Institute for Research & Innovation

    Tacoma, Washington

  • Melbourne Brain Centre Austin Hospital

    Melbourne, Australia

  • Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital

    South Brisbane, Australia

  • The Children's Hospital Westmead Dept. of Neurology and Neurosurgery

    Westmead, Australia

  • Universitair Ziekenhuis Antwerpen

    Antwerp, Belgium

  • Centre Hospitalier Universitaire Sainte-Justine

    Montreal, Canada

  • British Columbia Children's Hospital BCCH

    Vancouver, British Columbia, Canada

  • Danish National Epilepsy Centre

    Dianalund, Denmark

  • French Ref centre Necker Hospital Paris

    Paris, France

  • Epilepsiezentrum / Neuropädiatrie Hedwig-von-Rittberg-Zentrum Für Kinder und Jugendliche

    Berlin, Germany

  • Krankenhaus Mara Epilepsie-Zentrum Bethel

    Bielefeld, Germany

  • Epilepsiezentrum Freiburg

    Freiburg im Breisgau, Germany

  • Universitaetsklinikum Jena Klinik fuer Kinder- und Jugendmedizin Neuropaediatrie

    Jena, Germany

  • Klinik für Neuropädiatrie Universitätsklinikum Schleswig Holstein Campus Kiel

    Kiel, Germany

  • Kleinwachau Saechsisches Epilepsiezentrum Radeberggemeinnuetzige GmbH

    Radeberg, Germany

  • Universitaetsklinik fuer Kinder- und Jugendmedizin Abteilung III

    Tübingen, Germany

  • Schoen Klinik Vogtareuth Neuropaediatrie und Neurologische Rehabilitation, Epilepsiezentrum fuer Kinder und Jugendlische,Tagesklinik fuer Neuropaediatrie

    Vogtareuth, Germany

  • AOU Anna Meyer

    Florence, Italy

  • Istituto Pediatrico Giannina Gaslini Dipartimento di Neurologia

    Genova, Italy

  • A.O Carlo Poma

    Mantua, Italy

  • Instituto Neurologica Carlo Besta

    Milan, Italy

  • Ospedale Fatebenefratelli e Oftalmico

    Milan, Italy

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.